Introduction
Chronic lymphocytic leukemia (CLL) is a clonal B-cell malignancy characterized by several defects in both cellular and humoral immunity. 1 Despite knowledge of these immune abnormalities in patients with CLL, the relationship between normal T cells and neoplastic B cells is poorly understood.
Expansion and differentiation of normal antigen-specific T cells depends on two signals: binding of the TCR to antigen presented in the context of self major histocompatability (MHC) molecules and ligation of a costimulatory receptor. CD152 (CTLA-4; cytolytic T-lymphocyte-associated antigen-4) binds to CD80 and CD86 and plays a critical role in downregulating T-cell responses for maintenance of peripheral tolerance. 2 Although there is a large amount of information available regarding the expression of CD152 by T cells in normal individuals, [3] [4] [5] there are only few reports about the role of CD152 in T cells of patients with CLL. [6] [7] [8] [9] We hypothesized that T-cell anergy in previously untreated patients with CLL is the result of increased expression of CD152. Therefore, we investigated the expression of surface and cytoplasmic CD152 (sCD152 and cCD152, respectively) in freshly isolated T cells from peripheral blood of previously untreated patients with CLL. We found increased expression of CD152, which had functional significance confirmed by use of blocking monoclonal antibody (mAb) in proliferation assays with autologous and allogeneic CD40-activated CLL B-cell stimulators. We also evaluated for the CD4 þ /CD25 þ regulatory lymphocyte subset, known to constitutively express CD152. [10] [11] [12] Correlations with CD152 expression and patient's clinical characteristics were made. These findings have implications in new immunotherapeutic modalities for treatment of patients with CLL.
Materials and methods

Patients
Peripheral blood mononuclear cells (PBMCs) were collected from 40 previously untreated patients with CLL followed at UT MD Anderson Cancer Center (MDACC) and 13 healthy volunteers. Patient characteristics are summarized in Table 1 .
Isolation of peripheral blood mononuclear cells
PBMCs were isolated by density-gradient centrifugation over Histopaque 1077 (Sigma Chemical Co., St Louis, MO, USA), washed three times in 0.9% phosphate-buffered saline (PBS) (BioWhittaker) and stained with fluorochrome-conjugated mAbs. Immunoglobulin heavy chain variable gene (IgV H ) mutational status of CLL B cells was performed as previously described. 13 
Flow cytometric analysis
PBMCs were stained with mAbs conjugated with FITC, PE, CyC and APC fluorochrome (Becton-Dickinson, San Jose, CA, USA) against surface CD4, CD8, CD25 and CD152. Staining for cCD152 was performed using the Cytofix/Cytoperm Kit (Becton Dickinson, San Jose, CA, USA). Intracellular staining for Zap70 was performed as previously described. 13 Appropriate isotype controls were included for each sample. A total of 100 000 events were acquired for each sample using a FACSCaliber flow cytometer (Becton Dickinson, San Jose, CA, USA) and analyzed with FlowJo software (Tree Star Inc.). The results were expressed as the proportion of CD4
þ cells expressing CD152 antigen. The CD152 mean fluorescence intensity ratio (MFIR) was calculated in the CD4 þ and CD8 þ subsets. CD38 evaluation on CD19 þ lymphocytes was made during routine immunophenotype analysis at diagnosis.
T-cell stimulation by immobilized anti-CD3/anti-CD28 mAbs
The anti-CD3 (clone UCHT1) and anti-CD28 (clone 28.2) mAbs were purchased from BD PharMingen (San Diego, CA, USA).
For plate-bound anti-CD3 and anti-CD28 stimulation, 5.0 mg/ml of each mAb was added to each culture well of 24-well flat bottom plates (TPP, Switzerland), incubated at 41C overnight and then washed twice with PBS (BioWhittaker). PBMCs from patients with CLL and normal donors were cultured at 1 Â 10 7 cells/ml in AIM-V medium (Gibco) in mAb-coated wells. Cells were incubated at 371C in a humidified atmosphere containing 5% CO 2 for 12, 24 and 48 h. Negative controls were always performed by omitting the mAbs as well as by incubating cells in wells coated with isotype controls. After culture, cells were harvested and stained for flow cytometry analysis.
Coculture of normal T cells with PBMCs from patients with CLL
CLL cells were labeled with carboxyfluorescein diacetate, succinimidyl ester (CFDA, SE) (Molecular Probes Inc.) in order to distinguish them from normal cells. PBMCs from patients with CLL and normal controls were cocultured at 1:1 ratio (total: 1 Â 10 7 cells/ml) in AIM-V medium (Gibco) in 24-well flat bottom plates (TPP, Switzerland). Cultures were incubated at 371C in a humidified atmosphere containing 5% CO 2 for 24, 48 and 96 h. After culture, cells were harvested and stained for flow cytometry analysis.
To determine if a soluble factor was responsible for expression of CD152 by T cells of patients with CLL, normal PBMCs (1 Â 10 7 cells/ml) were cultured in 24-well flat bottom plates (TPP, Switzerland) in AIM-V medium (Gibco) plus 20% plasma from CLL patients. Cultures were incubated at 371C in a humidified atmosphere containing 5% CO 2 for 24 and 48 h. Cells were then harvested and stained for flow cytometry analysis.
T-cell proliferation against autologous and allogeneic CD40-activated CLL B cells A total of 1 Â 10 7 PBMCs from patients with CLL were cultured in 1 ml of RPMI 1640 (Gibco) supplemented with 2 ml of supernatant from HeLa cells stably transfected to express murine CD154 (HeLa CD154) in wells of a six-well plate (TPP, Switzerland) for 72 h. Negative controls were performed by culturing PBMCs in media alone or with culture supernatant from nontransfected HeLa. Cells were then harvested, washed and treated with mitomycin C (60 mg/ml) for 1 h at 371C to inhibit proliferation. These cells were then washed, resuspended in AIM-V medium (Gibco) and plated in 96-well U-bottom culture plates (Corning, Cambridge, MA, USA) at 5 Â 10 4 cells/ well for use as stimulator cells. Autologous T cells and allogeneic T cells from patients with CLL and normal donor T cells were isolated using anti-CD4-and anti-CD8-conjugated magnetic beads (Dynal, Lake Success, NY, USA) and added to wells to give a responder:stimulator ratio of 5:1. Anti-CD152 blocking mAbs (anti-human CD152; BD PharMingen, San Diego, CA, USA) were added at a concentration of 10 or 30 mg/ml. Controls with isotype-matched irrelevant monoclonal immunoglobulin (HOPC-1, Sigma), with anti-human HLA class I antigen (W6/32, Sigma), and media alone were performed. The final volume was 200 ml/well and plates were incubated at 371C and 5% CO 2 . Recombinant human IL-2 (Sigma) at a final concentration of 25 U/ml was added on days 0 and 4. After 7 days, cell cultures were supplemented with 0.5 mCi/well [ 
Statistical analyses
Statistical analyses of independent variables were performed using Student's t-test. Differences were considered statistically significant at Po0.05. Correlations between clinical characteristics and antigen expression on T cells were made by the Spearman rank order correlation test. Correlations were considered significant at Po0.05.
Results
Increased expression of sCD152 and cCD152 by T cells of patients with CLL
The mean percentage of CD4 þ cells expressing sCD152 was significantly higher for patients with CLL than normal donors (5.0 vs 0.82%; Po0.01) ( Table 2 ). The mean percentage of Table 2) .
Patients with CLL and normal donors were also evaluated for expression of cCD152. Our study was initially focused on expression of sCD152; however, given the potential functional importance, we began evaluating expression of cCD152 in the latter 19 patients studied. The mean percentage of CD4 þ cells expressing cCD152 was significantly higher for patients with CLL than normal donors (40.4 vs 6.9%; Po0.01) ( Table 2 ). The mean percentage of CD8 þ cells expressing cCD152 was also significantly higher in patients with CLL (16.9 vs 1.3%; Po0.05) ( Table 2 Ex vivo culture induces expression of sCD152 and cCD152 on T cells Ex vivo culture of PBMCs from patients with CLL and normal donors demonstrated a spontaneous expression of sCD152 and cCD152 on T cells and only for sCD152 (Figure 1 ). This was observed to a less extent in normal T cells (Figure 1) . A platebound culture method with anti-CD3 alone or in combination with anti-CD28 mAbs did not increase expression of CD152 (Figure 1 ). Coculture with PBMCs or plasma from patients with CLL failed to induce expression of cCD152 or sCD152 in T cells from normal donors (data not shown).
CD152 blockade enhances T-cell proliferation against autologous CD40-activated CLL B cells
In order to evaluate the functional role of CD152 in CLL T cells, we performed lymphocyte proliferation reactions with isolated T cells and autologous or allogeneic CD40-activated CLL B cells with or without CD152 blockade using anti-CD152 mAb. CD152 blockade enhanced T-cell proliferation in both allogeneic and autologous lymphocyte proliferation reactions (Figures 2 and 3) . The major effect was obtained using CD154-treated PBMCs as stimulators.
Clinical correlations with CD152 expression
Associations between patient clinical characteristics and CD152 expression were made by Spearman rank order correlation test. The following were evaluated for correlation with CD152 expression, CD4 
Discussion
We found a significantly higher proportion of T cells expressing surface and cytoplasmic CD152 in patients with CLL compared to normal donors. Scrivener et al 8 previously described increased cCD152 expression in unstimulated T cells from patients with CLL. In contrast to our study, they found a reduction in the number of circulating T cells expressing sCD152; however, for sCD152, only data after stimulation with phytohemagglutinin and anti-CD3 mAb were reported. Furthermore, Scrivener et al collected blood samples either from untreated patients or patients who had not received treatment in the preceding 6 months. A longer period of time without treatment could be necessary for obtaining a complete immune reconstitution. In Scrivener et al's study, the results were T cells express CD152 in B CLL M Motta et al obtained from freshly isolated PBMCs or PBMCs cultured for 48 h with stimuli, with or without B-cell depletion. Moreover, the analyses were conducted on CD2 þ cells and no data were reported for PBMCs cultured in the absence of stimuli. Our study represents a detailed analysis of CD152 expression on different T-cell subsets from patients with CLL. In fact, we conducted our
Interestingly, we found a spontaneous increase in cCD152 expression on T cells from patients with CLL with culture in CD152 expression by T cells from patients with CLL and normal donors, after 24 h of stimulation with anti-CD3 mAb. Freshly isolated PBMCs were cultured in AIM-V culture medium alone or with anti-CD3 mAb or murine IgG1, as described in Materials and methods. After 24 h of culture, cells were harvested and stained with anti-CD4, anti-CD8, anti-CD25 and anti-CD152 fluorochrome-conjugated mAb and flow cytometry analysis was performed as described in Materials and methods. Allogeneic T-cell proliferation with and without CD152 blockade. Freshly isolated PBMCs from patients with CLL were cultured in media alone or media supplemented by HeLa wild type or HeLa-CD154 supernatants. After 72 h, cells were harvested, treated with mitomycin C and used as stimulators in allogeneic mixed lymphocyte reactions (MLRs). Freshly isolated allogeneic T cells from normal donors (a) or patients with CLL (b) were added to wells, to give a responder:stimulator ratio of 5:1 in a final volume of 200 ml. Culture conditions consisted of AIM-V media alone, 30 mg/ml anti-CD152 mAb, 30 mg/ml anti-CD152 mAb plus 10 mg/ml anti-HLA mAb (W6/ 32), 10 mg/ml anti-HLA mAb (W6/32) alone or 30 mg/ml HOP-C isotype control mAb of irrelevant specificity. MLRs were than developed as described in Materials and methods. The mean cpm values of triplicate wells are indicated 7s.d. The data of one of three representative patients and normal controls are presented.
T cells express CD152 in B CLL M Motta et al AIM-V medium (Figure 1 ). This increased expression was also observed to a lesser extent for sCD152 and could not be significantly enhanced by stimulation with immobilized anti-CD3, alone or in combination with anti-CD28 (Figure 1) . To determine if a soluble factor or a cell-cell contact mechanism was responsible for this spontaneous increase in CD152 expression by CLL T cells, PBMCs from normal donors were cultured with plasma (20%) from patients with CLL or with PBMCs from patients with CLL. No increase in CD152 expression was seen (data not shown). Therefore, the mechanism for the ex vivo increased CD152 expression on T cells from patients with CLL but not in normal donors remains unclear. Normal individuals may also have a suppressive mechanism to maintain low-level CD152 expression.
The functional role of CD152 was also studied. Since CLL B cells are known to be poor stimulators in proliferation assays 14, 15 we used CD40-activated CLL B cells as stimulators. We demonstrated that T-cell proliferation was markedly increased when CD152 was blocked using anti-CD152 mAb. The major effect was observed when CD40-activated CLL B cells were used as stimulators. An increase in autologous and allogeneic T-cell proliferation was also observed with CLL B cells cultured in culture supernatant from wild-type HeLa cells and media-treated controls, suggesting that CD152 blockade may overcome the CLL T-cell hyporesponsiveness. These data may have important implications in developing further therapies for patients with CLL.
The increased proportion of CD4 þ /CD25 þ /CD152 þ T cells in patients with CLL is an important and previously unreported finding. Recent studies [10] [11] [12] have shown that a population of peripheral human CD4 þ /CD25 þ T cells with regulatory function constitutively express cytoplasmic CD152, which can be induced on the surface upon activation. 16 The function of regulatory CD4 þ /CD25 þ T cells is crucially dependent on signaling via CD152. Active suppression by T regulatory cells plays an important role in the downregulation of T-cell responses to foreign and self-antigens. This study is the first report that patients with CLL have a significantly higher proportion of CD4 þ /CD25 þ T cells with high-level constitutive expression of CD152 compared to normal controls.
Analysis of clinical and biological characteristics that correlated with CD4
þ cells showed an inverse correlation with serum IgG and IgA levels. This finding suggests a potential indirect role of CD152 in the hypogammaglobulinemia that develops in patients with CLL. Supporting this hypothesis, in an in vitro murine model, engagement of CD152 inhibited IgG1 and IgE production. 17 Furthermore, CD152 knockout mice show higher basal serum levels of all Ig isotypes compared with wild-type mice, ranging from 10-fold for IgM, IgG2a, IgG2b and IgG3, to 100-fold for IgG1 and IgA, to several thousand-fold for IgE. 18 We found a positive correlation between the proportion of CD4
þ T cells and advanced Rai stage and poor prognosis cytogenetics. Furthermore, the lymphocyte expression of sCD152 was associated with ZAP-70 expression on CLL B cells. One could speculate that the CD4 þ /CD25 þ /CD152 þ T cells in CLL may inhibit host immune responses against leukemia cells and contribute to the disease progression. In fact, several studies 19, 20 have demonstrated the role of regulatory T cells in promoting immunotolerance in cancer patients.
Conclusion
In conclusion, there is a significant increase in the proportion of T cells expressing CD152 and the phenotype of regulatory T cells that may function in the immune suppression and hyporesponsiveness that characterize CLL.
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